Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
- Recruiting
- Dec 9, 2015
- 1 min read
EMN12/HOVON129 Study
Phase 2: To evaluate progression-free survival in adult pPCL patients by incorporation of carfilzomib and lenalidomide in induction, consolidation, and maintenance therapy
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.
HOVON HO129 PCL
Multicenter, intergroup, phase 2 study
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.
Start Date: 2015-08-10
Stop Date: 2023-08-10
Netherlands Trial Register - Trial NL5202 (NTR5350)
Locations
Belgium
Denmark
Italy
Norway
The Netherlands
653.MYELOMA: THERAPY, EXCLUDING TRANSPLANTATION| NOVEMBER 13, 2019
Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study
This trial was registered at www.trialregister.nl as NTR5350
Conclusions: KRd induced deep hematologic responses after 4 cycles of therapy (≥VGPR in 80% and ≥CR in 33%) without early death. Toxicity consisted of 20% grade 3 and 27% grade 4 events, occurred mainly during the first cycle of induction, and was manageable with appropriate interventions. In conclusion, KRd provides efficient and rapid disease control, which is essential to prevent early mortality because of irreversible disease complications and to improve survival of patients with this aggressive plasma cell proliferative disorder.
